Last updated: November 14, 2024
Sponsor: Massachusetts General Hospital
Overall Status: Completed
Phase
2
Condition
Oral Facial Pain
Treatment
Dexmedetomidine / Ketamine / Lidocaine
Clinical Study ID
NCT04724759
2020P003873
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients aged 18 to 75 (inclusive)
Scheduled for TMJ surgery (including both unilateral and bilateral procedures)
Planned arthroscopic surgical procedure
Preoperative plan to discharge the same day
Exclusion
Exclusion Criteria:
Inability to provide written informed consent
Pregnant patients
Open TMJ Surgeries
Planned overnight admission
Mental status disorder or patient who are unable to communicate
Study Design
Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Dexmedetomidine / Ketamine / Lidocaine
Phase: 2
Study Start date:
June 18, 2021
Estimated Completion Date:
April 23, 2023
Study Description
Connect with a study center
Massachusetts General Hospital
Boston, Massachusetts 02114
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.